No Opioids, No Addiction: FDA Approves First New Type of Painkiller in Decades
Suzetrigine prevents pain signals from reaching the brain and doesn't give an opioid-like high, making it non-addictive—but it's expensive.
FDA approves new type of non-addictive painkiller from Boston drug company
The drug represents a new pathway to treating people with pain due to surgeries or traumatic injuries, avoiding the addictive ...
SchaeffersResearch.com41m
Biotech Stock Rises After FDA Approves Non-Opioid Painkiller
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) stock is up 6% at $465.02 at last glance, after the U.S. Food and Drug ...
The Daily Record (Maryland)48mOpinion
FDA approves painkiller designed to eliminate risk of addiction associated with opioids
Federal officials on Thursday approved a new type of pain pill designed to eliminate the risks of addiction and overdose ...
healthday54m
FDA Approves First New Non-Opioid Pain Pill in Decades
The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction ...
New type of non-opioid pain medication approved by FDA
The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class ...
Medscape56m
FDA OKs First-In-Class Nonopioid Pain Med Suzetrigine
Suzetrigine selectively inhibits the NaV1.8 pain-signaling pathway in the peripheral nervous system and provides effective ...
Vertex Pharmaceuticals price target raised to $545 from $520 at BMO Capital
BMO Capital analyst Evan Seigerman raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $545 from $520 and keeps an Outperform ...
FDA approves new type of non-opioid pain medication in two decades
FDA approves new type of non-opioid pain medication in two decades - The new drug will be many times more expensive than a ...
The Sentinel1h
FDA Approves Journavx: A New Non-Opioid Pain Relief Solution for Millions
This category includes pain that can pop up due to injuries, following surgeries, or as a symptom of an illness. What makes Journavx different is its unique way of working; instead of acting on the ...